Figures & data
Table I. Characteristics of randomized controlled trials included in the meta-analysis.
Figure 2. Risk ratios of major adverse cardiac events (primary end-point) associated with drug-coated balloon versus the control treatment in patients with drug-eluting stent restenosis. The size of the data marker is proportional to the weight of the individual studies, measured as the inverse of the variance in the study by the Mantel–Haenszel procedure.
![Figure 2. Risk ratios of major adverse cardiac events (primary end-point) associated with drug-coated balloon versus the control treatment in patients with drug-eluting stent restenosis. The size of the data marker is proportional to the weight of the individual studies, measured as the inverse of the variance in the study by the Mantel–Haenszel procedure.](/cms/asset/8673361c-b0c6-4935-9f2b-592141a7f24c/iann_a_952329_f0002_b.jpg)
Figure 3. Risk ratios of death (A), myocardial infarction (B), target lesion revascularization (C), and recurrent binary restenosis (D) associated with drug-coated balloon versus the control treatment in patients with drug-eluting stent restenosis. The size of the data marker is proportional to the weight of the individual studies, measured as the inverse of the variance in the study by the Mantel–Haenszel procedure.
![Figure 3. Risk ratios of death (A), myocardial infarction (B), target lesion revascularization (C), and recurrent binary restenosis (D) associated with drug-coated balloon versus the control treatment in patients with drug-eluting stent restenosis. The size of the data marker is proportional to the weight of the individual studies, measured as the inverse of the variance in the study by the Mantel–Haenszel procedure.](/cms/asset/f3a0612b-1a06-4d0a-8a7f-f2df55ccafc4/iann_a_952329_f0003_b.jpg)